-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

64 Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AML
Hematology Disease Topics & Pathways:
Non-Biological therapies, Therapies
Saturday, December 10, 2022: 10:15 AM

Harry P. Erba, MD, PhD1, Amir T. Fathi, MD2,3, Ghayas C. Issa, MD4, Jessica K. Altman, MD5, Pau Montesinos, MD, PhD6*, Mrinal M. M. Patnaik, MD7, James M. Foran, MD8, Stephane De Botton, MD, PhD9*, Maria R. Baer, MD10, Gary J. Schiller, MD11, Roland B. Walter, MD, PhD, MS12, Marina Kremyanskaya, MD, PhD13, Kristen M. Pettit14, Stephen A Strickland, MD, MSCI15, Blake Tomkinson, PhD, MBA16*, Marilyn Tabachri, RN, BSN16*, Mollie Leoni, MD16*, Stephen Dale, MD16* and Eunice S. Wang, MD17

1Leukemia Program, Duke University Medical Center, Durham, NC
2Director of Leukemia Program, Massachusetts General Hospital, Boston, MA
3Associate Professor of Medicine, Harvard Medical School, Boston, MA
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
6Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain
7Division of Hematology, Mayo Clinic, Rochester, MN
8Division of Hematology/Oncology and Blood and Marrow Transplanation and Cellular Therapy, Mayo Clinic, Jacksonville, FL
9Department of Haematology, Institut Gustave Roussy, Villejuif, France
10University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
11David Geffen School of Medicine at UCLA, Los Angeles, CA
12Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
13Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
14Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
15Vanderbilt-Ingram Cancer Center, Nashville, TN
16Kura Oncology, Boston, MA
17Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Histone-lysine-N-methyltransferase 2A (KMT2A) is a central regulator of target genes that drive leukemogenic transformation. KMT2A rearrangements (KMT2Ar) and nucleophosmin 1 mutations (NPM1m), founding events in leukemia, occur in 5-10% and 30% of acute myeloid leukemia (AML) patients (pts), respectively. KMT2Ar functions in a protein complex that requires menin to cause epigenetic dysregulation in AML. KMT2Awt-menin also cooperates with NPM1m causing dysregulation of an overlapping set of leukemogenic genes dependent on KMT2A-menin interaction. Thus, the strong rationale for targeting menin in KMT2Ar/NPM1m AML.

We present here preliminary KOMET-001 (NCT04067336) data, an ongoing Phase (P) 1/2 study of ziftomenib (KO-539), an inhibitor of KMT2A-menin interaction, in adult pts with relapsed/refractory (R/R) AML. Ziftomenib is dosed orally, once daily, in 28-day cycles.

P1a dose escalation enrolled 30 adult pts with R/R AML regardless of genotype. Pts received 50-1000 mg ziftomenib to assess safety, tolerability, pharmacokinetics, and anti-leukemic activity. Median age was 65.5 years (range [r] 22-85); 33%/13% had KMT2Ar/NPM1m AML. Pts had a median of 3 prior therapies (r 1-10), with 17% having ≥ 1 prior stem cell transplant (SCT).

In P1a, treatment-emergent adverse events (TEAEs) ≥ Grade (Gr) 3 in ≥ 10% of all pts (N=30) were anemia, pneumonia (27%); neutropenia (17%); thrombocytopenia (13%); febrile neutropenia, decreased appetite (10%). Two dose-limiting toxicities (DLTs) occurred: pneumonitis (400 mg) and differentiation syndrome (DS, 1000 mg); per protocol, the DLT in 1/1 pt at 1000 mg resulted in de-escalation.

Clinical benefit with disease control (eg, decreasing blast counts [BC] or hydroxyurea requirement) occurred across dose levels. At 100 mg, 1 complete remission (CR) was observed in a pt with SETD2, RUNX1 mutations. At 200 mg, the 2 NPM1m pts responded (1 experienced a CR without measurable residual disease [MRD-] with >100 weeks duration (ongoing), and 1 had morphologic leukemic-free state [MLFS]). At 600 mg, 1 of 2 KMT2Ar pts had stable disease with significantly decreased BC lasting >4 months.

P1b dose-validation explored 2 P1a doses (200/600 mg) in 24 pts with KMT2Ar/NPM1m AML to determine an optimal biologically active dose. KMT2Ar/NPM1m pts randomized to 200/600 mg were 9/3 and 6/6. Median age was 46 years (r 31-82), and 33% had ≥1 prior SCT. The 200/600mg pts had a median of 2.5/4 prior therapies (r 1-12/2-8).

In P1b, TEAEs ≥ Gr 3 in ≥ 10% of all pts (N=24) were anemia, febrile neutropenia, neutropenia, thrombocytopenia (25% each); DS, leukocytosis (17% each); sepsis, leukopenia (13% each). At 200 mg (N=12), TEAEs ≥ Gr 3 in ≥ 10% were neutropenia, thrombocytopenia (33% each); febrile neutropenia, anemia, sepsis (25% each); DS, leukocytosis, respiratory failure (17% each). At 600 mg (N=12), TEAEs ≥ Gr 3 in ≥ 10% were febrile neutropenia, anemia (25% each); DS, leukocytosis, neutropenia, thrombocytopenia, leukopenia, diarrhea (17% each).

The on-target effect of DS occurred in 7 P1b pts. At 200 mg, 3 were KMT2A pts, of which 2 had events ≥ Gr 3 including 1 death. Of the 4 pts at 600 mg, 2 were Gr 3 (1 each KMT2A/NPM1), and 2 were Gr 2 (1 each KMT2A/NPM1). Since implementation of DS Guidance, reported DS event severity has declined.

P1b clinical efficacy was dose-dependent. At 200 mg, changes in bone marrow (BM) morphology and stable/decreasing BC were seen. Three pts were dose-escalated to 600 mg with improvement: 1 achieved a BM BC < 5% and significant reduction of high burden extramedullary disease despite persistence of a small disease focus; 1 had significantly reduced BC and disease control; 1 attained MLFS and remains on treatment. At 600 mg, 25% of P1b pts had a best response of CR/CR with partial hematologic recovery (CRh); 33.3% of NPM1m pts achieved CR/CRh. Composite CR was 33% with 75% MRD-. Overall response rate (ORR) was 42%. Pts who experienced DS had an ORR of 75%. At data cutoff, 50% of pts remain on treatment.

Overall, P1a results demonstrated a manageable safety profile and preliminary efficacy that informed the P1b doses to determine the optimal biologically active dose. P1b results suggest that with appropriate DS management, ziftomenib is well tolerated. Additionally, the 600 mg dose demonstrates meaningful signs of efficacy in heavily pretreated R/R AML pts, warranting further investigation of ziftomenib as a monotherapy and in combination with rational therapeutic partners.

Disclosures: Erba: Gilead/Forty Seven: Research Funding; Forma Therapeutics: Research Funding; Kura Oncology: Consultancy, Research Funding; Trillium Therapeutics: Consultancy; Janssen Oncology: Consultancy; Daiichi Sankyo: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Glycomimetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; MacroGenics: Consultancy, Research Funding; Covance (Abbvie): Consultancy, Other: Independent Review Committee, Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy; PTC therapeutics: Research Funding; ALX Oncology: Research Funding; Takeda: Consultancy; Celgene: Consultancy, Other, Speakers Bureau; Astellas Pharma: Consultancy; Amgen: Consultancy, Research Funding; Agios: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Fathi: Takeda: Consultancy; Mablytics: Consultancy; EnClear: Consultancy; Forma: Consultancy; Celgene/BMS: Consultancy, Other: Clinical Trial Support; Amgen: Consultancy; Novartis: Consultancy; Abbvie/Servier: Consultancy, Other: Clinical Trial Support; Astellas: Consultancy; Kite: Consultancy; Foghorn: Consultancy; Morphosys: Consultancy; Immunogen: Consultancy; AbbVie, Agios, Bristol Myers Squibb, Servier, and Takeda: Research Funding; PureTech: Consultancy; Genentech: Consultancy; Ipsen: Consultancy; Orum: Consultancy; MorphoSys, Novartis, Pfizer, Seattle Genetics, Takeda, Trillium Therapeutics, and Trovagene: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie, Agios, Amgen, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Foghorn Therapeutics, Forty Seven, Inc., Genentech, Ipsen, Kite Pharma, Kura Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees. Issa: Novartis, Kura Oncology, Nuprobe: Consultancy; Celgene, Kura Oncology, Syndax, Merck, Cullinan and Novartis: Research Funding. Altman: AbbVie: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; BioSight: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: reimbursement for travel, Research Funding; GlycoMimetics: Other: Data monitoring committee member; AbbVie, Astellas: Consultancy; ALX Oncology, Amgen, Aprea, Aptos, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Fujifilm, Immunogen, Kartos, Loxo: Research Funding; Kura Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Syros Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Montesinos: Menarini/Stemline: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Otsuka: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Kura Oncology: Consultancy; Incyte: Consultancy; Gilead: Consultancy, Speakers Bureau; Takeda: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding, Speakers Bureau; Astellas: Consultancy, Speakers Bureau; Ryvu: Consultancy; Beigene: Consultancy; Nerviano: Consultancy; Abbvie: Consultancy, Research Funding, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau. Patnaik: Kura Oncology, Stem Line Pharmaceuticals: Research Funding. Foran: BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Daichi Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; DISC Medicine: Research Funding; Roivant: Research Funding; Actinium Pharmaceuticals: Research Funding; Astellas: Research Funding; Astex: Research Funding; Sellas: Research Funding; Pfizer: Research Funding. De Botton: Celgene: Consultancy, Honoraria, Speakers Bureau; Agios: Consultancy, Honoraria, Research Funding; Forma Therapuetics: Honoraria, Research Funding; Astellas: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Syros: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Bayer: Consultancy, Honoraria; Seattle Genetics: Honoraria; Janssen: Consultancy, Honoraria; Pierre Fabre: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Servier: Consultancy. Baer: Kura Oncology: Research Funding; AbbVie: Research Funding; Takeda: Research Funding; Ascentage: Research Funding; Forma: Research Funding; Kite: Research Funding. Schiller: AstraZeneca: Honoraria; Takeda: Research Funding; Stemline: Speakers Bureau; Sangamo: Research Funding; Samus: Research Funding; Cyclacel: Research Funding; Janssen: Research Funding; Daiichi-Sankyo: Research Funding; CTI: Research Funding; Celgene: Consultancy, Research Funding, Speakers Bureau; Jazz: Consultancy; Amgen: Current equity holder in publicly-traded company, Honoraria; Stemline: Research Funding; Mateon: Research Funding; Geron: Research Funding; Cellerant: Research Funding; Actuate: Research Funding; Arog: Research Funding; Onconova: Research Funding; Medimmune: Research Funding; Constellation: Research Funding; Trovagen: Research Funding; Cellectis: Research Funding; FujiFilm: Research Funding; Deltafly: Research Funding; Tolero: Research Funding; Gamida: Research Funding; Novartis: Honoraria, Other: Speaker fees, Research Funding; PreCOG LLC: Research Funding; Sellas: Research Funding; Pfizer: Research Funding; Karyopharm: Research Funding, Speakers Bureau; Regimmune: Research Funding; Johnson & Johnson: Current equity holder in publicly-traded company; Deciphera: Research Funding; Forma: Research Funding; Ono Pharma: Honoraria; Millennium: Research Funding; Kite, a Gilead Company: Research Funding, Speakers Bureau; Genentech-Roche: Research Funding; AVM Biopharma: Research Funding; Glycomimetics: Research Funding; AltruBio: Research Funding; Gilead: Research Funding; Bristol Myers Squibb: Current equity holder in publicly-traded company, Speakers Bureau; Incyte: Other: speaker fees, Research Funding, Speakers Bureau; Astellas: Research Funding, Speakers Bureau; Agios: Consultancy, Honoraria; Actinium: Research Funding; AbbVie: Research Funding, Speakers Bureau. Walter: Stemline Therapeutics: Research Funding; MacroGenics: Consultancy, Research Funding; Kura Oncology: Consultancy, Research Funding; ImmunoGen: Research Funding; Janssen Global Services, LLC: Consultancy; Bristol Myers Squibb, Inc: Consultancy; Kite Pharma, Inc: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding; Arog Pharmaceuticals: Research Funding; Janssen Research and Development: Research Funding; Astellas Pharma US, Inc: Consultancy; Kronos Bio, Inc: Consultancy; New Link Genetics: Consultancy; Pfizer, Inc: Consultancy, Research Funding; Race Oncology LTD: Consultancy; GSK: Consultancy; Genentech: Consultancy; Celgene, Inc: Consultancy, Research Funding; AbbVie: Consultancy; Selvita: Research Funding; Aptevo Therapeutics: Consultancy, Research Funding; Amphivena Therapeutics, Inc: Current equity holder in publicly-traded company; Amgen: Consultancy, Research Funding; Agios: Consultancy, Research Funding; BioLineRx, LTd: Consultancy, Research Funding; Boston Biomedical, Inc: Consultancy; BerGenBio, ASA: Consultancy; Orum Therapeutics, Inc.: Consultancy. Kremyanskaya: Kura: Research Funding; Chimerix: Research Funding; Kronos: Research Funding; Incyte: Consultancy, Research Funding; BMS: Research Funding; Constellation Pharmaceuticals, Inc., a MorphoSys Company: Consultancy, Research Funding; Ionis: Research Funding; Protagonist Therapeutics: Consultancy, Research Funding. Pettit: AbbVie, CTI Biopharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Blueprint Biomedicines, Image Biosciences, Kura Oncology, Macogenics, PharmaEssentia, Protagonis: Research Funding. Strickland: AbbVie, BerGenBio, Genentech, Kura Oncology, and Syros: Consultancy, Honoraria. Tomkinson: Kura Oncology: Consultancy, Current Employment, Current equity holder in publicly-traded company. Tabachri: Kura Oncology: Current Employment. Leoni: Kura Oncology: Current Employment. Dale: Kura Oncology: Current Employment. Wang: Kura Oncology: Consultancy, Honoraria, Other: Advisory Board, Steering Committee, Speakers Bureau; Abbvie: Consultancy, Honoraria, Other: member of data monitoring committee ; Mana Therapeutics: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria, Other: Advisory Board; Novartis: Consultancy, Honoraria, Other: Advisory Board; Kite Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; Genentech: Consultancy; Takeda: Consultancy, Honoraria, Other: Advisory Board; Dava Oncology: Consultancy, Speakers Bureau; Rafael Pharmaceuticals: Other: Data Safety Monitoring Committee; Gilead: Consultancy, Honoraria, Other: Advisory Board; Daiichi Sankyo: Consultancy, Honoraria, Other: Advisory Board; PTC Therapeutics: Consultancy, Honoraria, Other: Advisory Board; Macrogenics: Consultancy; Stemline Therapeutics: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; Astellas: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board.

*signifies non-member of ASH